Coinbase CEO's anti-aging startup NewLimit is raising $435 million, tripling its valuation
Colleen Cabi
·
2026-06-03
·
via Quartz
The South San Francisco biotech plans to begin its first human trial of a liver cell-reprogramming therapy ne…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。